

Figure S1. Study flow chart.

Table S1. Differences in the seizure count between baseline and follow-up.

differences in seizure count									
before examination						after examination			
period									
[m - months. d – days]	12 m	6 m	3 m	1 m	7 d	1 m	3 m	6 m	12 m
mean	1.12	(-)0.41	0.41	0.08	(-)0.02	0.00	(-)0.76	(-)1.31	0.39
± SEM	± 1.49	± 0.73	± 0.30	± 0.11	± 0.03	± 0.14	± 0.49	± 0.69	± 1.28
median	0	0	0	0	0	0	0	0	0
min-max	(-)30 - 88	(-)25 - 34	(-)6 - 14	(-)3 - 5	(-)1 - 1	(-)6 - 5	(-)30 - 5	(-)32 - 10	(-)34 - 60

Table S2. Differences in the levels of molecules between the no-seizure and seizure group at baseline.

	patients without seizures			patients with seizures			p
	mean	median	min-max	mean	median	min-max	
	± SEM			± SEM			
MMP-9	605.70	544.93	311.76	850.18	701.52	125.22	0.1038
[ng/ml]	± 104.37		- 1899.46	± 90.48		- 2555.34	
TIMP-1	218.93	260.23	29.60	244.00	256.50	2.69	0.5801
[ng/ml]	± 30.33		- 402.59	± 19.61		- 464.72	
MMP-2	279.58	243.00	155.99	293.89	286.50	133.86	0.4192
[ng/ml]	± 32.29		- 548.59	± 17.45		- 538.70	

CCL-2	311.02		112.47	331.93		118.12	
[pg/ml]	± 39.68	277.58	- 548.00	± 25.24	315.43	- 771.43	0.6107
P-sel	83.55		6.62	114.25		9.05	
[ng/ml]	± 20.27	38.60	- 228.47	± 10.75	110.00	- 240.68	0.0969
TIMP-2	161.79		112.23	144.88		95.16	
[ng/ml]	± 11.48	156.67	- 257.58	± 4.06	142.73	- 205.19	0.2982
S100B	83.34		0.29	27.30		0.35	
[pg/ml]	± 40.65	41.38	- 571.13	± 4.56	19.13	- 144.50	0.1806
ICAM-1	175.47		103.34	184.48		110.39	
[ng/ml]	± 15.20	161.40	- 310.27	± 12.33	167.27	- 437.03	0.7651
TSP-2	32.24		11.17	28.55		8.83	
[ng/ml]	± 4.47	29.94	- 61.04	± 3.19	21.74	- 96.59	0.3034
MMP-9			1.33 -			0.66 -	
/TIMP-1	5.31 ± 1.99	2.08	27.92	8.78 ± 3.80	2.85	131.21	0.4585
MMP-2							
/TIMP-2	1.74 ± 0.18	1.55	1.01 - 3.61	2.04 ± 0.11	2.05	0.83 - 3.86	0.0904

Table S3. Differences in the levels of molecules in patients without seizures at baseline and follow-up.


	baseline			follow-up			p
	mean	median	min-max	mean	median	min-max	
	± SEM			± SEM			
MMP-9	605.70		311.76	515.55		68.53	
[ng/ml]	± 104.37	544.93	- 1899.46	± 82.06	444.79	- 1148.87	0.1981
TIMP-1	218.93		29.60	72.04		3.83	
[ng/ml]	± 30.33	260.23	- 402.59	± 11.96	81.29	- 151.74	0.0013
MMP-2	279.58		155.99	210.85		97.15	
[ng/ml]	± 32.29	243.00	- 548.59	± 20.17	201.43	- 413.73	0.1319
CCL-2	311.02		112.47	430.44		178.57	
[pg/ml]	± 39.68	277.58	- 548.00	± 47.27	382.71	- 747.29	0.0047
P-sel	83.55		6.62	126.41		19.51	
[ng/ml]	± 20.27	38.60	- 228.47	± 29.61	69.47	- 318.63	0.3003
TIMP-2	161.79		112.23	154.52		106.93	
[ng/ml]	± 11.48	156.67	- 257.58	± 7.25	158.10	- 182.97	0.6378

S100B	83.34		0.29	63.33		0.50	
[pg/ml]	± 40.65	41.38	– 571.13	± 28.23	27.55	– 411.25	0.7299
ICAM-1	175.47		103.34	177.75		112.25	
[ng/ml]	± 15.20	161.40	– 310.27	± 18.10	166.28	– 369.73	0.9250
TSP-2	32.24		11.17	25.67		13.23	
[ng/ml]	± 4.47	29.94	– 61.04	± 4.01	20.77	– 66.60	0.3305
MMP-9			1.33 –	33.77		0.45 –	
/TIMP-1	5.31 ± 1.99	2.08	27.92	± 21.01	6.61	299.90	0.0355
MMP-2							
/TIMP-2	1.74 ± 0.18	1.55	1.01 - 3.61	1.37 ± 0.11	1.36	0.54 – 2.42	0.1771

Table S4. Differences in the levels of molecules in patients with seizures at baseline and follow-up.

	baseline			follow-up			p
	mean ± SEM	median	min-max	mean ± SEM	median	min-max	
MMP-9	850.18		125.22	423.49		10.15	
[ng/ml]	± 90.48	701.52	– 2555.34	± 59.58	322.61	– 1699.80	0.0004
TIMP-1	244.00		2.69	112.03		9.55	
[ng/ml]	± 19.61	256.50	– 464.72	± 9.07	117.71	– 216.35	<0.0001
MMP-2	293.89		133.86	196.84		41.32	
[ng/ml]	± 17.45	286.50	– 538.70	± 17.40	211.62	– 496.85	0.0008
CCL-2	331.93		118.12	436.33		93.14	
[pg/ml]	± 25.24	315.43	– 771.43	± 34.12	403.29	– 1299.29	0.0008
P-sel	114.25		9.05	172.17		16.47	
[ng/ml]	± 10.75	110.00	– 240.68	± 18.24	147.72	– 389.76	0.0038
TIMP-2	144.88		95.16	161.51		92.84	
[ng/ml]	± 4.06	142.73	– 205.19	± 5.73	164.07	– 244.59	0.0337
S100B	27.30		0.35	33.94		0.75	
[pg/ml]	± 4.56	19.13	– 144.50	± 14.67	11.11	– 516.25	0.2383
ICAM-1	184.48		110.39	162.72		36.03	
[ng/ml]	± 12.33	167.27	– 437.03	± 9.35	154.18	– 340.99	0.0270
TSP-2	28.55		8.83	26.62		11.22	
[ng/ml]	± 3.19	21.74	– 96.59	± 1.99	22.60	– 63.50	0.6822

MMP-9 /TIMP-1	8.78 ± 3.80	2.85	0.66 – 131.21	6.64 ± 1.60	2.93	0.07 – 38.91	0.9347
MMP-2 /TIMP-2	2.04 ± 0.11	2.05	0.83 - 3.86	1.25 ± 0.11	1.29	0.29 - 3.41	0.0001






Figure S2. The influence of molecule levels on seizure count during follow-up; at 7 days: (a) MMP-2; (b) CCL-2; (c) MMP-9; 1 month (d) MMP-2; (e) CCL-2; (f) MMP-9; 3 months (g) MMP-2; (h) CCL-2; (i) MMP-9; 6 months (j) MMP-2; (k) CCL-2; (l) MMP-9; 12 months (m) MMP-2; (n) CCL-2; (o) MMP-9. GLM.